
Eli Lilly’s tirzepatide is ”a new start” within type 2 diabetes and could essentially eradicate the disease, professor Sten Madsbad, who is a consultant at the endocrinology department at Hvidovre hospital, tells Danish journal Sundhedspolitisk Tidsskrift.
This comes after detailed results from a phase III study, Surmount-1, which demonstrated weight loss of up to 22.5% of baseline body weight, were presented at the US diabetes conference, ADA 2022.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app